BPC-157 Evidence Guide
BPC-157 has an unusually large preclinical healing literature, but no completed human efficacy trial or approved formulation. The 2026 independent rat tendon study was less convincing for BPC-157 than for TB-500 and did not show a benefit from combining them. It is useful for studying repair mechanisms, not a clinically validated treatment.
Our Take
BPC-157 has an unusually large preclinical healing literature, but no completed human efficacy trial or approved formulation. The 2026 independent rat tendon study was less convincing for BPC-157 than for TB-500 and did not show a benefit from combining them. It is useful for studying repair mechanisms, not a clinically validated treatment.
- Evidence context
- Preclinical study of tendon, gastrointestinal, and tissue-repair mechanisms
- Evidence grade
- Level B
- Confidence
- Moderate
- Reference context
- Reported research reference: No validated human dose; published references are animal or laboratory protocols
BPC-157 Field Guide
A plain-English guide to the claims people make about BPC-157, what the evidence actually says, and which uncertainties matter most.
Built as a field reference: common claims first, evidence quality second, then safety, regulatory context, and the primary-source map.
Benefits and Evidence
- Tendon & Ligament Healing: Level B, mostly non-human evidence - In a rat Achilles tendon transection model (Staresinic et al., J Orthop Res, 2003), BPC-157 at 10mcg/kg daily (intraperitoneal) produced significantly improved collagen fiber organization, tensile strength, and functional recovery at day 14 vs. saline controls. Similar results at the lower 10ng/kg dose suggest a wide therapeutic window. At least 8 additional tendon/ligament models replicate this basic finding, though all are from the same Zagreb research group.
- Gut Health & Protection: Level B, mostly non-human evidence - Over 20 rodent studies document protection of gastric mucosa against diverse insults: indomethacin-induced ulcers, ethanol lesions, cysteamine-induced duodenal ulcers, and acetic acid colitis. A systematic review by Sikiric et al. (Curr Pharm Des, 2013) summarizes this body of work. Crucially, BPC-157 was stable in gastric acid in these studies, making oral administration plausible. No human efficacy data has been published despite a Phase 2 IBD trial registration.
- Muscle Recovery: Level C, mostly non-human evidence - Rat crush-injury and transection models show BPC-157 accelerates muscle fiber regeneration and reduces fibrosis formation at injury sites. Effect sizes are consistent across studies but all originate from the same lab. No human muscle recovery data exists.
- Bone Healing: Level C, mostly non-human evidence - Rat segmental bone defect and pseudoarthrosis models demonstrate improved bone remodeling with systemic BPC-157 administration. Evidence base is smaller than the tendon/GI literature and methodological details (blinding, histomorphometry protocols) are inconsistently reported.
- Neuroprotection: Level C, mostly non-human evidence - Rat models of peripheral nerve crush injury and spinal cord transection show improved recovery with BPC-157. Vukojević et al. (Brain Behav, 2020) demonstrated reduced hippocampal damage after ischemia-reperfusion in rats. The translational relevance to human neurological injury is highly speculative at this stage.
Side Effects and Warnings
- No significant toxicity reported at tested doses in several rodent studies
- No genotoxicity or mutagenicity identified in preclinical safety assessments
- Human adverse-event frequency cannot be estimated from the available evidence
- No completed, published human safety trial establishes short- or long-term safety
- Not FDA-approved for any medical condition; classified as a research chemical
- FDA cites immunogenicity, peptide-related impurities, and insufficient human safety information as compounding concerns
- Virtually all evidence is from a single research group at the University of Zagreb - independent replication is limited
- Long-term human safety is completely unknown
Research Dosage References
- <strong>Animal research reference</strong> - 10 ng/kg to 10 mcg/kg - Protocol-dependent - Range reported across rat injury models. These routes and doses are not validated or transferable human dosing instructions.
Mechanism of Action
BPC-157 appears to promote healing through at least four overlapping mechanisms, though most evidence is from rodent models and in vitro systems: 1. Angiogenesis via VEGF upregulation: Multiple studies from the Sikiric group show BPC-157 increases VEGF expression at injury sites, promoting formation of new blood vessels that support tissue repair. The angiogenic effect has been documented in both tendon and GI injury models. 2. Nitric oxide (NO) system modulation: BPC-157 interacts with the NO/cGMP signaling pathway. In rat models of NSAID-induced gastric damage, the protective effect was partially blocked by NO inhibitors (L-NAME), suggesting NO generation is mechanistically relevant. This same pathway may contribute to anti-inflammatory effects. 3. Growth hormone receptor and FAK-paxillin pathway: Chang et al. (2014) demonstrated in tendon fibroblasts that BPC-157 increases growth hormone receptor expression and activates the FAK-paxillin signaling cascade, which drives fibroblast migration - a critical early step in tendon repair. 4. Cytoprotection of GI epithelium: BPC-157 protects against a striking range of GI insults in animal models - ethanol, indomethacin, cysteamine, acetic acid - through mechanisms that include reducing pro-inflammatory cytokine release and maintaining mucosal integrity. The compound is stable in gastric acid, which is relevant to its potential oral bioavailability.
Legal Status
BPC-157 is not FDA-approved for any indication. FDA has identified safety concerns for compounded BPC-157, including immunogenicity, peptide-related impurities, and insufficient information to determine whether it would harm humans. WADA names BPC-157 in section S0 of the 2026 Prohibited List, so it is prohibited at all times in tested sport.
Primary Sources
- Tendon healing by BPC 157 in rats: results assessed by electron microscopy and force-velocity tests. J Orthop Res, 2003.
- Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (IBD): stable gastric pentadecapeptide BPC 157 as both glioblastoma standard-of-care and IBD standard-of-care. Curr Pharm Des, 2011.
- Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 2014.
- BPC 157 and the healing of various tissues. Adv Exp Med Biol, 2021.
- The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain Behav, 2020.
- Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157: NO-system relation, dose- and time-dependent cytoprotection/healing, J Physiol Paris.. J Physiol Paris, 2010.
- Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. J Clin Med, 2026.
- BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics, 2026.
Quick Answers
Where is the strongest evidence for BPC-157?
BPC-157 has an unusually large preclinical healing literature, but no completed human efficacy trial or approved formulation. The 2026 independent rat tendon study was less convincing for BPC-157 than for TB-500 and did not show a benefit from combining them. It is useful for studying repair mechanisms, not a clinically validated treatment. Evidence context: Preclinical study of tendon, gastrointestinal, and tissue-repair mechanisms.
What are the main side effects of BPC-157?
BPC-157 side effects and warning signals include No significant toxicity reported at tested doses in several rodent studies, No genotoxicity or mutagenicity identified in preclinical safety assessments, Human adverse-event frequency cannot be estimated from the available evidence, No completed, published human safety trial establishes short- or long-term safety, and Not FDA-approved for any medical condition; classified as a research chemical.
What evidence level is BPC-157?
BPC-157 is rated Level B; the listed research status is Phase 2.